Singapore, Jan. 13 -- Novartis, a leading global innovative medicines company, has announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida, US.

The built-for-purpose, state-of-the-art facility represents another milestone in the company's $23 billion US investment announced in April 2025, further expanding manufacturing capabilities to meet growing demand for these cutting-edge cancer treatments. Novartis is scaling US manufacturing to bring innovative medicines closer to patients, so treatments are researched, made, and delivered with greater speed, reliability, and access in the communities where people live.The new 35,000-square-foot facility in Winter Park, Florida, will come on...